You are currently viewing a new version of our website. To view the old version click .

An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2

Special Issue Information

Dear Colleagues,

The 8th International Conference on Protein Kinase CK2 (www.uks.eu/ck2), organized by Matthias Montenarh and Claudia Götz, will be held at the Faculty of Medicine of Saarland University, in Homburg, Germany, from 6–9 September, 2016.

Protein kinase CK2 is a serine/threonine kinase, which is highly conserved in evolution. Knock-out experiments have shown that this enzyme is absolutely necessary for cell viability. The enzyme is highly expressed in rapidly proliferating cells, which goes along with an elevated enzyme activity. Protein kinase CK2 is involved in a broad range of signaling pathways, regulating proliferation, differentiation, apoptosis, or senescence. Recent advances towards the characterization of the three-dimensional structure of protein kinase CK2 and its subunits will undoubtedly yield important new insights into its regulation, and the functions of CK2. Moreover, with two inhibitors of the enzyme presently in clinical phase II trials, human protein kinase CK2 has appeared as an emerging target for cancer diseases.

Speakers at the conference are cordially invited to contribute original research papers or reviews to this Special Issue of Pharmaceuticals.

Prof. Dr. Joachim Jose
Prof. Dr. Marc Le Borgne
Prof. Dr. Lorenzo A. Pinna
Prof. Dr. Mathias Montenarh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • protein kinase
  • cancer disease
  • signal transduction
  • therapeutic target
  • structural biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Pharmaceuticals - ISSN 1424-8247Creative Common CC BY license